Saturday, 6th October Australasian Melanoma Conference 2018

"Champions against melanoma: taking control of Australia's cancer"

8:00am: Breakfast served
8:30am: Welcome and Opening from Michael Sukkar MP
8:35am: Narelle Williams - Exercise behaviours and fatigue in patients receiving immunotherapy for advanced melanoma: a cross-sectional survey
8:40am: Discussion hosted by Tom Elliott
9:25am: Wrap Up

• Adjuvant systemic therapies for melanoma - Grant McArthur

• Is there a role for cancer vaccines in the treatment of melanoma? - Riccardo Dolcetti
• The power of natural born killers - Jai Rautela
• Putting sentinels to work: harnessing dendritic cells for cancer immunotherapy - Meredith O'Keeffe
• Changing the tumor vasculature to regulate immune cell trafficking in melanoma - Claudine Bonder

• Breakthroughs in systemic therapy for brain metastases - Michael Davies
• Radiotherapy advances for treating cerebral metastases - David Kok

9:55 AM Panel Clinical Cases

Kate Drummond, Michael Davies, David Kok, Gerald Fogarty

• Your patient has metastatic disease. What are the options? - Rachel Roberts-Thomson
• Side-effects of cancer immunotherapy - Mark Voskoboynik
• Dermatological issues with systemic therapy - Pablo Fernandez-Penas

10:00 AM Clinical Cases 

• Immunotherapy combinations - which and why - Tara Mitchell
• Cold to hot transformation with intratumoral therapy in melanoma - Adil Daud
• Lessons from CAR-T-cell therapy for GD2-positive melanomas - Tessa Gargett
• Mesenchymal cell subsets in melaoma metastases - Rod Dunbar
• Biology and implications of immunotherapy toxicities - Rosalie Stephens

• Debate Topical and injectable therapies for cutaneous metastases  - Diona Damian
• Debate Surgery is the optimal management for oligo metastatic disease  - Jonathan Zager
• Debate Surgery has no role for oligo-metastatic disease - Andrew Haydon
• Debate Radiation for oligometastatic disease should be offered regardless! - Rohan Nair

11:45 AM Clinical Cases

• Dermoscopic Subtypes of benign naevi and their significance - Peter Soyer
• Long and short term sequential dermoscopy - Amanda Oakley
• Vascular clues and amelanotic melanoma with dermoscopy - Pascale Guitera
• Dermoscopy of Melanocytic lesions of Acral sites and the Nail Apparatus - Alex Chamberlain
• When should I refer for confocal microscopy? - Caterina Longo

• Predicting patient outcomes - Richard Scolyer

• Where to next with targeted therapies?  - Georgina Long
• The potential of CDK4 inhibition in anti-melanoma therapy - Karen Sheppard
• Targeting pro-survival BCL-2 proteins for the treatment of melanoma - Marco Herold
• Repurposing epigenetic drugs to prime for immunotherapy - Nikola Bowden

• Survivorship: issues for patients with melanoma and other cancers - Michael Jefford
• Post-treatment follow-up and investigations for high-risk melanoma - Haryana Dhillon
• Post-treatment follow-up and investigations for high-risk melanoma - Robyn Saw
• Survivorship issues faced by patients with early stage melanoma - Donna Milne
• Not another one! - Monitoring for secondary primary melanomas - Yan Pan

• Approaches to biopsy of suspicious lesions - Victoria Mar
• Interpreting the pathology report for optimal management - Catriona McLean
• Update on excision margins and practical aspects of melanoma surgery - Angela Webb
• Advanced surgery - which flap and when to graft? - Michael Weymouth

3:20 PM Audience Questions & Panel Discussion

• Biomarker-based prediction of melanoma outcomes in high-risk patients - Helen Rizos
• Uses and biology of circulating melanoma cells - Mel Ziman
• Liquid biopsy and imaging in the monitoring of therapy response - Shahneen Sandhu

• Curing Merkel cell carcinoma: Progress and Challenges - Shailendar Bhatia
• Immunotherapy for Recurrent or Metastatic Cutaneous SCC - Danny Rischin
• Hedgehog pathway inhibitors for BCC - Pablo Fernandez-Penas

• Ensuring the quality of melanoma care: The National Melanoma Guidelines - the consumer perspective   - Alison Button-Sloan
• Ensuring the quality of melanoma care: The National Melanoma Guidelines - the clinician perspective - John Thompson
• What it feels like for an understudied group of survivors- the survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors and combination BRAF and MEK inhibitors - Julia Lai-Kwon
• Treatment toxicity vs treatment benefit - what is the right balance? - Grant McArthur

Speaker: Graham Mann